SELE
E-selectin
As of the edition of 20 October 2026, SELE (E-selectin, UniProt P16581) has 3 drugs tested at it and 3 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P16581
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 17
- Disease areas
- Blood and lymph; Cancer; Inherited and neonatal; Heart and blood vessels; Immune system; Pregnancy and women's health; Skin and connective tissue; Urinary and reproductive
- Registered trials of its drugs
- 28
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 3 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Uproleselan | Stopped | Phase 3 | none listed |
| Rivipansel | Stopped | Phase 3 | none listed |
| GMI-1359 | Stopped | Phase 1 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Biossil | Route A |
| Crescent Biopharma | Route A |
| Apollomics | Route A |
The other 0 companies at SELE
In the product3 companies in all; 0 are not named here, and no score is.
See the 3 companies at SELE, ranked, with the facts behind eachRequest access. Nothing is shown until you do.